Satellite symposia are non-commercial, grant- funded learning activities that are planned and conducted by the corporate community in conjunction with AMCP 2026. Satellite symposia offer continuing pharmacy education (CPE) credit, and some offer continuing medical education (CME) credit and continuing nursing education (CNE) credit.
Registration, content, and continuing education are the sole responsibility of the provider. There is no fee for pre-registering for these educational activities, as registration is for planning purposes only.
- Monday, April 13, 2026 | Lunch | Optimizing Cardiorenal-Metabolic Health: A Managed Care Guide to Integrating SGLT2 Inhibitor Therapy
-
Location: 102AB | 2:00 pm - 4:00 pm CT
Optimizing Cardiorenal-Metabolic Health: A Managed Care Guide to Integrating SGLT2 Inhibitor Therapy- Provider: Pharmacy Times Continuing Education
- Supported by: This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company
- Continuing education: Managed Care Pharmacists
- Contact hours: 1.5
Program Description
Cardiorenal-metabolic (CRM) syndrome is the overlap of type 2 diabetes, heart failure (HF), and chronic kidney disease (CKD), and the condition presents clinical and economic burdens due to progressive organ damage and frequent hospitalizations. While SGLT2 inhibitors have revolutionized therapy for patients with and without diabetes, their optimal use is often limited by clinical inertia. Additionally, across the CRM continuum, SGLT2 inhibitors consistently reduce hospitalizations and adverse events that drive high health care costs. The rapid expansion of clinical indications for SGLT2 inhibitors beyond glycemic control has created a shift in the management of CRM conditions. Their appropriate use, however, requires that pharmacists and managed care professionals be adequately informed about guideline-directed evidence to optimize clinical and economic outcomes. This program balances clinical evidence for SGLT2 inhibitors with payer application. The expert-led discussion will provide the tools to design value-based formularies and integrated care models to improve utilization of SGLT2 inhibitors while managing the total cost of care.
Learning Objectives
- Identify the interconnected pathophysiology, clinical progression, and economic burden of cardiorenal-metabolic diseases to improve early risk stratification and opportunities for integrated management.
- Analyze current clinical evidence, guideline recommendations, and comparative data for SGLT2 inhibitors across the cardiorenal-metabolic spectrum to inform care strategies for patients.
- Illustrate evidence-based formulary and benefit design strategies that incorporate real-world evidence, cost-effectiveness analyses, and outcomes-based contracting models to improve patient access, individualized care, optimize adherence, and align the total cost of care with the clinical value of SGLT2 inhibitors.
Program Manager
Kylie Ferrentino
Pharmacy Times Continuing Education
kferrentino@pharmacytimes.com
- Monday, April 13, 2026 | Dinner | Aligning Clinical Evidence With Managed Care Decision-Making in the Evolving Myelofibrosis Treatment Landscape
-
Location: 102AB | 6:00 pm - 8:00 pm CT
Aligning Clinical Evidence With Managed Care Decision-Making in the Evolving Myelofibrosis Treatment Landscape- Provider: Pharmacy Times Continuing Education
- Supported by: This educational activity is supported by an independent medical education grant from GSK
- Continuing education: Managed care, oncology
- Contact hours: 1.5
Program Description
Myelofibrosis, a chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, splenomegaly, cytopenias, and debilitating constitutional symptoms, presents substantial challenges in both clinical management and health system resource utilization. Despite the availability of Janus kinase inhibitors (JAKis), disease progression, anemia, and thrombocytopenia remain persistent barriers to optimal outcomes. In recent years, there has been a push for individualized treatment sequencing strategies and the integration of emerging disease-modifying agents. The treatment landscape has expanded beyond JAKi monotherapy to include ruxolitinib-based combinations and agents with novel mechanisms of action and the potential to not only reduce spleen size and improve symptoms but also modify the disease trajectory. Oncology pharmacists in managed care roles must be ready to interpret emerging clinical trial data and assess how these novel therapies can be integrated into practice. This program presents the latest evidence on guideline-directed therapy selection, molecular risk stratification, and real-world data to inform formulary and coverage decisions. Participants will explore strategies to optimize transitions between therapies, manage treatment-related anemia, and address the economic and quality-of-life burden associated with myelofibrosis. Expert speakers will break down clinical trial evidence, current guidelines, and value-based care principles, equipping pharmacists to support patient-centered outcomes and ensure the appropriate, cost-effective use of novel and established therapies in myelofibrosis.
Learning Objectives
- Analyze the latest clinical evidence, guideline updates, and emerging therapeutic strategies in myelofibrosis to inform evidence-based formulary decisions and ensure the appropriate use of available drug therapies.
- Apply best practices for sequencing and transitioning patients with myelofibrosis to subsequent therapies following progression or intolerance, with attention to safety, efficacy, and supportive care considerations.
- Examine the clinical and economic burden of myelofibrosis and strategies to optimize patient outcomes and value-based care through integration of novel therapies and real-world evidence.
Program Manager
Kylie Ferrentino
Pharmacy Times Continuing Education
kferrentino@pharmacytimes.com
- Tuesday, April 14, 2026 | Breakfast | A Managed Care Perspective on Hard-to-Control Hypertension: Understanding the Risks and Challenges in Uncontrolled and Resistant Hypertension
-
Location: 102AB | 6:00 am - 8:00 am CT
A Managed Care Perspective on Hard-to-Control Hypertension: Understanding the Risks and Challenges in Uncontrolled and Resistant Hypertension- Provider: Pharmacy Times Continuing Education
- Supported by: This activity is supported by an educational grant from AstraZeneca.
- Continuing education: A wide audience of managed care, payor, pharmacy benefit, pharmacy director, pharmacy benefit managers, specialty pharmacy directors, and any other pharmacist and/or healthcare professional attending AMCP Annual meeting who are interested in the role of targeted treatment for hard-to-control hypertension.
- Contact hours: 1.5
Program Description
Uncontrolled and treatment-resistant hypertension continue to present significant clinical and public health challenges, affecting millions of adults and driving disproportionate rates of cardiovascular and renal morbidity. This session will explore the spectrum of uncontrolled and resistant hypertension, highlighting underlying pathophysiologic mechanisms, with a focus on the role of aldosterone dysregulation within the renin-angiotensin-aldosterone system. The epidemiology, high-risk patient groups, and clinical consequences of persistent blood pressure elevation will also be discussed. Faculty presenters will review recent updates to the 2025 American College of Cardiology and American Heart Association guidelines and discuss contemporary treatment paradigms, including common barriers to achieving control despite multidrug therapy. The program will also spotlight novel therapeutic advances, such as aldosterone synthase and endothelin receptor antagonists, that target key biologic drivers of disease. Participants will gain insight into managed care considerations, including cost-effectiveness, formulary decision-making, and strategies to optimize equitable access, to improve outcomes for patients with hard-to-control hypertension.
Learning Objectives
- Examine the incidence and prevalence of hypertension in the Uinited States, the risks associated with uncontrolled or resistant hypertension, the burden of long-term hypertension, and the unmet treatment need
- Interpret new treatment guidelines, standard options for controlling blood pressure, and new and emerging therapies that may change the treatment landscape for patients with hard-to-control hypertension
- Explore the high cost of treating uncontrolled or treatment-resistant hypertension, the downstream effects of hard-to-control hypertension, and managed care strategies to promote access and positive patient outcomes
Program Manager
Kylie Ferrentino
Pharmacy Times Continuing Education
kferrentino@pharmacytimes.com
- Tuesday, April 14, 2026 | Lunch | Contemporary Data, Differentiation, and Decision-Making in Hypertrophic Cardiomyopathy: A Guide to Cardiac Myosin Inhibition for the Managed Care Professional
-
Location: 101AB | 11:30 am - 1:30 pm CT
Contemporary Data, Differentiation, and Decision-Making in Hypertrophic Cardiomyopathy: A Guide to Cardiac Myosin Inhibition for the Managed Care Professional- Provider: PeerVoice in partnership with USF Health (ACPE-accredited provider)
- Supported by: Cytokinetics
- Continuing education: Pharmacists and other professionals practicing in the managed care setting
- Contact hours: 1.5
Program Description
In this activity, experts will discuss the rationale for the use of cardiac myosin inhibition for individuals with hypertrophic cardiomyopathy (HCM), and explore evidence-based treatment pathways that optimise pharmacotherapeutic management, access, and outcomes for those living with HCM.
Presenters
Course Director
Anjali Tiku Owens, MD
University of Pennsylvania
Philadelphia, Pennsylvania, USA
Faculty
Andrew Willeford, PharmD, PhD
UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences
UC San Diego Health
San Diego, California, USA
Faculty
Rachel Lavell, PharmD, BCCP
University of Chicago Medicine
Chicago, Illinois, USALearning Objectives
- Differentiate between obstructive and non-obstructive hypertrophic cardiomyopathy (oHCM and nHCM) based on their pathophysiology and current guideline-directed management strategies
- Evaluate the efficacy and safety of cardiac myosin inhibition as monotherapy or first-line therapy for oHCM in comparison to beta-blockade
- Compare available cardiac myosin inhibitors (CMIs) based on their pharmacology, trial designs, outcomes, and practicalities of use
- Propose evidence-based treatment pathways for individuals with oHCM that promote optimal patient care, clinical outcomes, access to therapy, and overall resource utilization
- Assess emerging data and the investigational treatment landscape for nHCM
Program Manager
Blanka Pchalkova
PeerVoice
blanka.pchalkova@peervoice.com
- Tuesday, April 14, 2026 | Lunch | High-Stakes Access: Aligning Managed Care Policy With the Urgency of Treatment in Duchenne Muscular Dystrophy
-
Location: 102AB | | 11:30 am - 1:30 pm CT
High-Stakes Access: Aligning Managed Care Policy With the Urgency of Treatment in Duchenne Muscular Dystrophy- Provider: Pharmacy Times Continuing Education
- Supported by: This activity is supported by an independent medical educational grant from Dyne Therapeutics.
- Continuing education: A wide audience of managed care, payor, pharmacy benefit, pharmacy director, pharmacy benefit managers, specialty pharmacy directors, and any other pharmacist and/or healthcare professional attending AMCP Annual
- Contact hours: 1.5
Program Description
Duchenne muscular dystrophy (DMD) is a rare, X-linked recessive disease that typically presents in early childhood and primarily affects males. DMD is characterized by progressive muscle weakness and degeneration that can lead to decreased quality of life and complications involving the respiratory, orthopedic, and cardiac systems. The pathophysiology of DMD involves frame-shift mutations, most often the deletion of one or more exons in the dystrophin gene, which result in the absence or insufficiency of functional dystrophin protein required to keep muscle cells intact. The therapeutic landscape is rapidly evolving with a focus on disease modification, particularly through exon-skipping therapies that aim to restore the genetic reading frame to produce a functional protein. This session will specifically review underlying genetic mechanisms in DMD and examine the clinical evidence supporting both approved and emerging exon-skipping therapies. After participating, pharmacists and managed care decision-makers will be better equipped to apply best practices for patient-centered care, facilitate timely access to appropriate treatments through informed coverage and formulary decisions, and coordinate multidisciplinary management to mitigate the clinical and economic burden of DMD.
Learning Objectives
- Explain the underlying genetic and physiological mechanisms of Duchenne muscular dystrophy (DMD), including the role of dystrophin and progressive muscle degeneration
- Analyze the evidence-based treatment recommendations for patients with DMD and the data supporting the use of new and emerging exon-skipping therapies.
- Explore best practices to support patient-centered treatment, coordination of care, and access to timely, appropriate therapies for patients with DMD
Program Manager
Kylie Ferrentino
Pharmacy Times Continuing Education
kferrentino@pharmacytimes.com - Tuesday, April 14, 2026 | Lunch | Managed Care Perspectives on Achieving Diabetes Treatment Goals Using New Monitoring Technology
-
Location: 104AB | 11:30 am - 1:30 pm CT
Managed Care Perspectives on Achieving Diabetes Treatment Goals Using New Monitoring Technology- Provider: Cornerstone Medical Education and American Academy of CME, Inc.
- Supported by: This activity is supported by an independent educational grant from Abbott Diabetes Care.
- Continuing education: This educational activity has been designed and developed for managed care pharmacists, and other managed care professionals, who help care for patients with diabetes through their role as a managed care clinician.
- Contact hours: This activity provides 1.5 ACPE contact hours (0.15 CEUs) of continuing education credit.
Program Description
Designed as an adaptive, timely, and engaging approach that includes a live satellite symposium at the 2026 AMCP Annual Meeting and a 12-month enduring on AMCPlearn.org, this initiative will provide managed care professionals with a comprehensive exploration of current quality measures in diabetes and best practices for using monitoring devices to meet these metrics. The critical role of the managed care professional in aligning managed care and provider clinical decision-making with current evidence and patient-specific factors to ensure appropriate management of diabetes will be a central theme and a point of incisive expert focus throughout the activity. Practical insights from expert faculty on overcoming healthcare disparities and inequities that can adversely affect patient outcomes in diabetes will be discussed, tangibly highlighting the imperative need for collaboration and the importance of individualized, data-driven, and equitable monitoring and treatment selection. Interactive questions will be employed to maintain engagement and assess learning throughout, and time permitting, an audience Q&A with the faculty will conclude the live event.
Learning Objectives
- Review the most recent updates to diabetes-related quality metrics.
- Examine the role of continuous monitoring in meeting diabetes quality metrics and improving patient outcomes.
- Evaluate data supporting the cost-effective use of advances in diabetes monitoring to improve patient outcomes.
- Assess diabetes monitoring utilization in practice via real-world patient case scenarios.
Program Manager
Bryan Taylor
Cornerstone Medical Education
bryan.taylor@cornerstonemeded.com
- Tuesday, April 14, 2026 | Lunch | Targeting BCMA in Early Relapsed/Refractory Myeloma: Translating New Clinical Evidence Into Managed Care Strategies
-
Location: 105AB | 11:30 am - 1:30 pm CT
Targeting BCMA in Early Relapsed/Refractory Myeloma: Translating New Clinical Evidence Into Managed Care Strategies- Provider: Clinical Care Options, LLC.
- Supported by: This educational activity is supported by independent medical education grants from GSK and Johnson & Johnson.
- Continuing education: This program is intended for oncology and managed care pharmacists and other healthcare professionals caring for patients with multiple myeloma.
- Contact hours: 1.5
Program Description
An accredited educational program designed for oncology pharmacists who manage patients with multiple myeloma (MM) to improve their ability to optimally utilize BCMA-targeted agents, including interaction with leading experts and discussions on the optimal integration of emerging data to improve patient outcomes.
Learning Objectives
- Assess the rationale for targeting BCMA in early R/R MM and analyze implications for formulary inclusion and treatment approaches to improve patient outcomes
- Apply guideline-informed frameworks to evaluate access, sequencing, and therapy decisions across BCMA modalities.
- Develop and implement evidence-based strategies for monitoring and managing TRAEs with BCMA-targeted antibody–drug conjugates by establishing protocols, supporting coverage decisions, and facilitating multidisciplinary communication
- Synthesize managed care perspectives when implementing BCMA-directed therapy in clinical practice
Program Manager
Suzanne Thatcher
Decera Clinical Education
sthatcher@deceraclinical.com
- Tuesday, April 14, 2026 | Dinner | Integrating Therapeutic Advances and Value-Based Models in Myasthenia Gravis Management
-
Location: 102AB | 6:00 pm - 8:00 pm CT
Integrating Therapeutic Advances and Value-Based Models in Myasthenia Gravis Management- Provider: Pharmacy Times Continuing Education
- Supported by: This activity is supported by an independent medical educational grant from UCB Inc.
- Continuing education: A wide audience of managed care, payor, pharmacy benefit, pharmacy director, pharmacy benefit managers, specialty pharmacy directors, and any other pharmacist and/or healthcare professional attending AMCP Annual meeting who are interested in the role of targeted treatment for hard-to-control hypertension.
- Contact hours: 1.5
Program Description
Generalized myasthenia gravis (gMG) is a chronic autoimmune disorder in which autoantibodies disrupt communication between nerves and muscles. This disruption leads to fluctuating muscle weakness that can severely impair vision, speech, swallowing, and respiratory function. Many patients experience unpredictable cycles of physical decline and fatigue that reduce independence, with approximately 15% of patients remaining refractory to standard treatments and at increased risk of life-threatening myasthenic crises. While traditional management relies on acetylcholinesterase inhibitors, corticosteroids, and non-steroidal immunosuppressants, the therapeutic landscape is shifting toward targeted biologics, including neonatal Fc receptor (FcRn) blockers and complement (C5) inhibitors. These newer therapies offer potentially improved disease control by interrupting key immune pathways, yet their integration is hindered by high costs, complex adverse effect management, and insurance coverage barriers. Managed care pharmacists are pivotal in navigating these challenges by developing utilization management strategies, implementing value-based care models, and coordinating multidisciplinary care to ensure sustainable access to specialty agents. This session features expert-led discussion on the latest clinical data and best practices to assess emerging therapies and apply value-based strategies, empowering managed care professionals to optimize patient-specific treatment decisions and improve long-term clinical and economic outcomes for those living with gMG.
Learning Objectives
- Apply knowledge of generalized myasthenia gravis (gMG) clinical features, symptom patterns, and disease burden to guide patient-specific treatment decisions.
- Employ gMG management protocols and emerging therapies to select treatments that target disease-driving mechanisms.
- Examine the economic burden of gMG to implement value-based strategies that guide utilization management of novel therapies.
Program Manager
K!ylie Ferrentino
Pharmacy Times Continuing Education
kferrentino@pharmacytimes.com
- Wednesday, April 15, 2026 | Breakfast | Optimizing Outcomes in Hereditary Angioedema: Managed Care Approaches to Diagnosis, Treatment, and Patient Quality of Life
-
Location: 102AB | 6:00 am - 8:00 am CT
Optimizing Outcomes in Hereditary Angioedema: Managed Care Approaches to Diagnosis, Treatment, and Patient Quality of Life- Provider: Pharmacy Times Continuing Education
- Supported by: This activity is supported by an independent medical educational grant from Ionis Pharmaceuticals, Inc.
- Continuing education: This program is targeting a wide audience of managed care, payor, pharmacy benefit, pharmacy director, pharmacy benefit managers, specialty pharmacy directors, and any other pharmacist and/or healthcare professional attending AMCP Annual meeting who are interested in the role of targeted treatment for HAE.
- Contact hours: 1.5
Program Description
Hereditary angioedema (HAE) is characterized by recurrent swelling of the skin and submucosal tissues, most commonly affecting the extremities, face, gastrointestinal tract, and airway. The management of HAE is complex, as frequency and severity of attacks vary widely between individuals and even within the same person over time. Acute on-demand treatment and prophylactic therapy options have emerged as the mainstays of HAE management. While each is effective, there are practical, safety, and economic limitations that affect real‑world use and patient quality of life. Challenges include burdensome routes of administration, treatment delays, breakthrough attacks despite prophylaxis, adverse effects, and high direct and system costs. This program will review clinical data for expanded long-term prophylaxis options in the HAE treatment landscape and focus on distinct profiles regarding efficacy, safety, and administration methods to support individualized treatment strategies. These expanded treatment options have the potential to reallocate healthcare expenditure from acute interventions toward preventive care strategies while simultaneously improving disease management. This discussion will also incorporate real-world data for long-term prophylaxis agents in HAE to equip managed care professionals and pharmacists to improve clinical, quality-of-life, and economic outcomes while still supporting patient access to appropriate agents for HAE treatment and management.
Learning Objectives
Investigate the multifaceted clinical and economic impact of hereditary angioedema (HAE), encompassing treatment expenditures, healthcare utilization patterns, and the downstream effects of current management approaches on patient outcomes. Distinguish among current and emerging prophylactic therapies by assessing their comparative efficacy, safety profiles, and routes of administration to inform personalized and cost-conscious treatment decisions. Interpret recent innovations in on-demand HAE therapies and examine how these agents contribute to reducing attack burden, improving quality of life, and decreasing healthcare resource use. Identify managed care strategies to ensure timely access to HAE treatments, fostering continuity of care, and advancing evidence-based, value-oriented management strategies.
Program Manager
Kylie Ferrentino
Pharmacy Times Continuing Education
kferrentino@pharmacytimes.com
- Wednesday, April 15, 2026 | Lunch | New Frontiers in Hyperkalemia Care: The Role of Managed Care Professionals and Novel Potassium Binders
-
Location: 101AB | 11:30 am - 1:30 pm CT
New Frontiers in Hyperkalemia Care: The Role of Managed Care Professionals and Novel Potassium Binders- Provider: Pharmacy Times Continuing Education
- Supported by: This activity is supported by an educational grant from AstraZeneca.
- Continuing education: managed care pharmacist
- Contact hours: 1.5
Program Description
1.5-hour educational activity will feature two faculty, a clinical expert and a managed care professional, as they discuss updates in hyperkalemia and best practices in applying the clinical data to the managed care considerations.
Learning Objectives
• Explain the pathophysiology, high-risk populations, recurrence patterns, and health burden of HK in CKD and HF patients.
• Compare the mechanisms, efficacy, safety profiles, and real-world impact of potassium binders in both acute and chronic HK settings.
• Explore the economic impact and operational barriers associated with HK management and how these affect access, adherence, and utilization of newer therapies.
Program Manager
Kylie Ferrentino
Pharmacy Times Continuing Education
kferrentino@pharmacytimes.com
- Wednesday, April 15, 2026 | Lunch | Redefining Value in Transthyretin Amyloidosis Cardiomyopathy Care: Innovations in Diagnosis, Treatment, and Access
-
Location: 102AB | 11:30 am - 1:30 pm CT
Redefining Value in Transthyretin Amyloidosis Cardiomyopathy Care: Innovations in Diagnosis, Treatment, and Access- Provider: Pharmacy Times Continuing Education
- Supported by: This activity is supported by an educational grant from Alnylam.
- Continuing education: managed care pharmacist
- Contact hours: 1.5
Program Description
Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is a progressive, life-threatening disease caused by the misfolding of transthyretin proteins into amyloid fibrils that deposit in the heart, leading to restrictive cardiomyopathy and heart failure. Despite its severity, ATTR-CM is frequently underdiagnosed or delayed as symptoms often overlap with more common conditions. This session is designed to equip managed care professionals and pharmacists with the clinical and economic insights necessary to resolve diagnostic and treatment delays in ATTR-CM. Through a review of current therapies, including established TTR stabilizers, as well as the expanding role of TTR gene silencers and other investigational agents, expert speakers will explore critical considerations in treatment sequencing, the interpretation of serum TTR as a biomarker, and the application of health economic data to inform sustainable formulary decisions. By highlighting the pivotal role of the managed care pharmacist in multidisciplinary teams, this program aims to optimize patient-centered access, improve therapy adherence, and leverage emerging diagnostic tools to reduce the systemic and economic burden of ATTR-CM.
Learning Objectives
- Identify key symptoms and common diagnostic pitfalls for transthyretin amyloidosis cardiomyopathy (ATTR-CM) and their impact on timely diagnosis and optimal resource use.
- Explain the comparative safety, efficacy, cost considerations, and mechanisms of action for available and emerging therapies for ATTR-CM.
- Apply team-based care models and health economic data to optimize managed care contributions to patient-centered access, therapy adherence, and sustainable formulary decisions for ATTR-CM.
Program Manager
Kylie Ferrentino
Pharmacy Times Continuing Education
kferrentino@pharmacytimes.com
- Wednesday, April 15, 2026 | Lunch | Improving Patient Outcomes in Fibrosing ILDs - Clinical and Managed Care Perspectives on the Evolving Landscape
-
Location: 104AB | 11:30 am - 1:30 pm CT
Improving Patient Outcomes in Fibrosing ILDs - Clinical and Managed Care Perspectives on the Evolving Landscape- Provider: Pharmacy Times Continuing Education
- Supported by: This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
- Continuing education: managed care pharmacist
- Contact hours: 1.5
Program Description
Fibrosing interstitial lung disease (F-ILD) encompasses a number of conditions characterized by common features, including fibrotic lung tissue, chronic cough, and breathlessness. The two primary categories are idiopathic pulmonary fibrosis (IPF), the most common form, and progressive pulmonary fibrosis (PPF), such as chronic hypersensitivity pneumonitis or connective tissue disease. These diseases both have poor clinical prognoses and represent a major clinical challenge because the loss of lung function is irreversible, leading to severe disability, high morbidity, and mortality. The current goal of therapy with antifibrotics is to slow disease progression rather than reverse existing damage, but gaps in care persist due to diagnostic delays and high discontinuation rates. New therapies under investigation have demonstrated the potential to provide options with novel mechanisms of action and potentially fewer systemic adverse effects. This session will detail the pathophysiology and clinical burden of F-ILDs, while differentiating between IPF and PPF. Clinical experts will present recent data for approved and late-stage emerging therapies alongside evidence-based guidelines that prioritize early treatment initiation. Additionally, the session will focus on strategies managed care professionals and pharmacists can apply to address the economic burden and access barriers of F-ILDs. As clinical data for these emerging therapies continues to become available, managed care professionals and pharmacists must ensure that formulary placement and prior authorization criteria are aligned with the latest evidence.
Learning Objectives
- Explain the pathophysiology and clinical burden of fibrosing interstitial lung diseases (F-ILDs), differentiating idiopathic pulmonary fibrosis (IPF) from progressive pulmonary fibrosis (PPF).
- Interpret recent clinical data for currently approved and emerging antifibrotic pharmacologic therapies for F-ILD to compare their potential impact on clinical care.
- Apply best practices and evolving treatment guidelines to facilitate evidence-based management for patients with F-ILD.
- Illustrate the clinical, financial, and treatment burden of F-ILD and how managed care professionals can facilitate appropriate access to timely interventions to mitigate these challenges.
Program Manager
Kylie Ferrentino
Pharmacy Times Continuing Education
kferrentino@pharmacytimes.com
- Wednesday, April 15, 2026 | Lunch | Mock P&T: Applying the Latest Evidence to Advance Managed Care Decision-Making in Retinal Vascular Disease
-
Location: 105AB | 11:30 am - 1:30 pm CT
Mock P&T: Applying the Latest Evidence to Advance Managed Care Decision-Making in Retinal Vascular Disease- Provider: PRIME Education LLC
- Supported by: Genentech, a member of the Roche Group.
- Continuing education: medical and pharmacy directors, pharmacists, and HCPs working in managed care settings (physicians, NPs, PAs, and medication therapy management (MTM)
- Contact hours: 1.5
Program Description
As the retinal vascular disease treatment landscape rapidly evolves with new anti-VEGF and anti-VEGF/Ang-2 therapies, innovative delivery modalities, and extended-interval dosing strategies, managed care professionals face growing pressure to make formulary decisions that balance clinical efficacy, cost, and timely patient access.
Join leading retina and managed care experts live in Nashville, TN or via livestream on April 15 in conjunction with 2026 AMCP Annual Meeting for a first-of-its-kind interactive satellite symposium designed as a mock Pharmacy and Therapeutics (P&T) Committee meeting.
This unique session places you at the center of evidence-based decision-making for neovascular age-related macular degeneration (nAMD), diabetic retinopathy/diabetic macular edema (DR/DME), and retinal vein occlusion (RVO).
Don't miss this opportunity to:
- Evaluate the latest clinical and real-world evidence on approved anti-VEGF and anti-VEGF/Ang-2 therapies
- Differentiate therapies by mechanism of action, delivery methods, and dosing regimens
- Participate as a "committee member" through interactive polling at key decision points
- Engage directly with expert faculty through live Q&A addressing top-of-mind questions from managed care decision-makers
- Access a downloadable Managed Care Decision-Makers Pocket Playbook for ongoing reference.
Learning Objectives
- Assess the burden of nAMD, DR/DME, and RVO, including clinical and socioeconomic impacts
- Differentiate anti-VEGF and anti-VEGF/Ang-2 treatments for nAMD, DR/DME, and RVO by mechanisms of action, delivery methods, and dosing regimens
- Evaluate clinical and real-world evidence on novel anti-VEGF and anti-VEGF/Ang-2 therapies in nAMD, DR/DME, and RVO and their implications for patient outcomes
- Align managed care decision-making with the latest evidence to support timely, appropriate patient access to anti-VEGF and anti-VEGF/Ang-2 therapies for nAMD, DR/DME, and RVO
Program Manager
Lainey Lewis
PRIME Education LLC
l.lewis@primeinc.org
- Wednesday, April 15, 2026 | Dinner | Uncomplicating the Complications of Systemic Lupus Erythematosus for Managed Care - A Focus on Nephritis
-
Location: 102AB | 11:30 am - 1:30 pm CT
Uncomplicating the Complications of Systemic Lupus Erythematosus for Managed Care - A Focus on Nephritis- Provider: Pharmacy Times Continuing Education
- Supported by: This educational activity is supported by an educational grant from Genentech, a member of the Roche Group.
- Continuing education: Managed Care Pharmacists
- Contact hours: 1.5
Program Description
Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease driven by immune‑complex–mediated inflammation that can involve the skin, joints, central nervous system, and kidneys. Organ damage accrues both from early inflammatory/fibrotic injury and from drug‑related toxicity, and one of the most severe manifestations is lupus nephritis (LN), which increases the risk of end-stage kidney disease and affects up to 40 % of patients. Management is challenged by the heterogeneity of SLE, wide variability in disease severity, and the presence of active or refractory disease despite standard of care (SOC) therapy. Despite recommendations for early and aggressive immunosuppression in SOC regimens, the precise moment to add a biologic or start a steroid taper is not always clear, and adverse effects and treatment failure remain a risk for a majority of patients. Novel biologic agents and emerging therapies target distinct pathways and offer the potential for improved efficacy and safety, but the effective use of these therapies requires managed care pharmacists to be active participants in coordinated care pathways and navigate complex regimens, ensure adherence, and drive policies that improve access to high-quality LN care for underserved populations. This session will review SLE epidemiology, classification criteria, clinical manifestations, and disease progression with a focus on LN. Participants will gain a comprehensive understanding of the clinical and economic impact of SLE and LN, as well as the the evolving therapeutic landscape and the strategic role of managed care pharmacists in value-based decision-making.
Learning Objectives
- Examine the epidemiology and pathophysiology of systemic lupus erythematosus (SLE) and lupus nephritis (LN) and the impact of disease progression on patient outcomes.
- Analyze clinical guidelines and new pharmacotherapy for the treatment of SLE and LN.
- Apply an evidence-based approach to optimizing outcomes and utilization management for the treatment of SLE and LN.
Program Manager
Kylie Ferrentino
Pharmacy Times Continuing Education
kferrentino@pharmacytimes.com
- Thursday, April 16, 2026 | Breakfast | From Biomarkers to Better Outcomes: The Impact of Immunotherapy on the Endometrial Cancer Landscape
-
Location: 102AB | 6:00 am - 8:00 am CT
From Biomarkers to Better Outcomes: The Impact of Immunotherapy on the Endometrial Cancer Landscape- Provider: Pharmacy Times Continuing Education
- Supported by: This educational activity is supported by an independent medical education grant from GSK
- Continuing education: Managed care, oncology
- Contact hours: 1.5
Program Description
Endometrial cancer is the most common gynecologic malignancy in developed countries, yet outcomes remain poor for patients with advanced, recurrent, or high-risk disease. Black women in particular experience disproportionately higher mortality despite lower incidence and often less access to guideline-concordant care. Tailoring treatment based on individual patient characteristics, such as molecular biomarkers or genetic mutations, is becoming increasingly important in cancer care. This program will equip oncology pharmacists and managed care professionals to navigate rapidly evolving immunotherapy-based treatment paradigms by connecting molecular biomarkers with optimal regimen selection, sequencing, and utilization management in recurrent and metastatic settings. Through discussion of pivotal trials of immune checkpoint inhibitor–chemotherapy combinations and PARP inhibitor–based strategies and current guideline recommendations, pharmacists will gain practical skills to individualize therapy based on stage, histology, biomarker profile, prior treatment, toxicity risk, and patient-specific factors. The activity will also address real-world challenges with biomarker testing workflows, interpretation of results, adverse effect monitoring, and cost-effectiveness of molecular testing and immunotherapy, highlighting how evidence-based formulary design, prior authorization criteria, and other managed care tools can promote equitable access, improve quality of life, and support value-based, guideline-driven care across diverse patient populations.
Learning Objectives
- Examine the use of predictive biomarkers to guide treatment selection with immunotherapy-based regimens in endometrial cancer and determine implications for utilization management strategies.
- Explore the evolving role of immune checkpoint inhibitors in recurrent or advanced endometrial cancer, based on recent clinical evidence and guideline recommendations.
- Investigate the impact of equitable access to immunotherapy in endometrial cancer on clinical outcomes, patient quality of life, and total cost of care in managed care populations.
Program Manager
Kylie Ferrentino
Pharmacy Times Continuing Education
kferrentino@pharmacytimes.com